Clinical trial
Study for the Treatment of Significant Steatosis With Xenical Followed by…
NCT00207311 · Brooke Army Medical Center, U.S. Fed · Completed
Key facts
| NCT number | NCT00207311 |
|---|---|
| Title | Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus |
| Official title | A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus |
| Acronym | HCVNASH |
| Lead sponsor | Brooke Army Medical Center, U.S. Fed |
| Collaborators | Hoffmann-La Roche Industry The Geneva Foundation |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Fatty Liver, Hepatitis C |
| Intervention type | Behavioral, Drug |
| Interventions | Xenical, Pegasys, Copegus, Xenicare Program |
| Enrollment | 30 |
| Start date | Aug 1, 2005 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Sep 21, 2005 |
| Last update posted | Feb 14, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: